Doraiswamy Vinayak
Known title: Chief Scientific OfficerCIK: 0001862458
Associated companies
Transaction History
| ATRC | ▼ Sell | Open Market | 6,000 | $233K | 7/28/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 636 | $15K | 6/30/2026 | View on chart |
| ATRC | ▼ Sell | Open Market | 5,000 | $141K | 5/15/2026 | View on chart |
| ATRC | ▼ Sell | Open Market | 5,000 | $149K | 3/12/2026 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 15,585 | $487K | 3/1/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 15,198 | $0 | 3/1/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 30,390 | $0 | 3/1/2026 | View on chart |
| ATRC | ▼ Sell | Open Market | 2,500 | $91K | 8/5/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 822 | $21K | 6/30/2025 | View on chart |
| ATRC | ▼ Sell | Open Market | 2,500 | $84K | 5/28/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 19,359 | $0 | 3/1/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 6,579 | $0 | 3/1/2025 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 9,672 | $375K | 3/1/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 707 | $14K | 6/28/2024 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 8,855 | $321K | 3/1/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 9,328 | $0 | 3/1/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 19,294 | $0 | 3/1/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 557 | $21K | 6/30/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 16,104 | $0 | 3/1/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 8,036 | $0 | 3/1/2023 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 4,793 | $186K | 3/1/2023 | View on chart |
| ATRC | ▼ Sell | Open Market | 4,983 | $229K | 9/15/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 350 | $12K | 6/30/2022 | View on chart |
| ATRC | ▼ Sell | Tax Withholding | 7,474 | $520K | 3/1/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 6,825 | $0 | 3/1/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 7,789 | $0 | 3/1/2022 | View on chart |
| ATRC | ▲ Buy | Grant | 24 | $1K | 12/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
BTIG raises AtriCure price target to $63
BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.
BTIG raises AtriCure price target to $63. BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.